Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA. Sudha P, et al. Among authors: gooding s. Clin Cancer Res. 2022 Jul 1;28(13):2854-2864. doi: 10.1158/1078-0432.CCR-21-3695. Clin Cancer Res. 2022. PMID: 35522533 Free PMC article.
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S, Ansari-Pour N, Kazeroun M, Karagoz K, Polonskaia A, Salazar M, Fitzsimons E, Sirinukunwattana K, Chavda S, Ortiz Estevez M, Towfic F, Flynt E, Pierceall W, Royston D, Yong K, Ramasamy K, Vyas P, Thakurta A. Gooding S, et al. Blood. 2022 Oct 20;140(16):1816-1821. doi: 10.1182/blood.2022015909. Blood. 2022. PMID: 35853156 Free PMC article.
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U. Kurata K, et al. Among authors: gooding s. Blood Cancer J. 2023 Jan 12;13(1):12. doi: 10.1038/s41408-023-00787-w. Blood Cancer J. 2023. PMID: 36631435 Free PMC article.
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U. Kurata K, et al. Among authors: gooding s. Blood Cancer J. 2023 Feb 7;13(1):24. doi: 10.1038/s41408-023-00793-y. Blood Cancer J. 2023. PMID: 36746923 Free PMC article. No abstract available.
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs AP, Kelly G, Patel M, Kim-Schulze S, Flynt E, Lagana A, Gooding S, Merad M, Jagganath S, Pierceall WE, Oppermann U, Thakurta A, Parekh S. Van Oekelen O, et al. Among authors: gooding s. Cell Rep Med. 2024 May 17:101584. doi: 10.1016/j.xcrm.2024.101584. Online ahead of print. Cell Rep Med. 2024. PMID: 38776911 Free article.
Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project.
Lomas OC, Gooding S, Cabes M, Dreau H, Wilson E, Polzella P; Genomics England Research Consortium; Ramasamy K, Hamblin AD. Lomas OC, et al. Among authors: gooding s. EJHaem. 2021 Aug 26;2(4):809-812. doi: 10.1002/jha2.276. eCollection 2021 Nov. EJHaem. 2021. PMID: 35845211 Free PMC article.
53 results